（文章来源：证券日报） 证券日报网讯 2月26日，新芝生物发布2025年年度业绩快报公告称，公司2025年实现营业收入 169713804.31元，同比增长0.96%；归属于上市公司股东的净利润35180806.67元，同比下降15.49%。 ...

Core Insights - Beckman Coulter Life Sciences has achieved a significant milestone in localizing its production in China with the launch of the Optima XPN-100 ultracentrifuge, marking the establishment of complete local production and quality validation capabilities for ultracentrifuges in the country [1][3] Group 1: Production and Quality Management - The local production of the Optima XPN-100 signifies the formation of an engineering and quality management system that supports high-end centrifuge manufacturing in China, laying a sustainable foundation for future localization of high-end instruments [3] - The Suzhou factory has developed a comprehensive process system that includes quality management, supply chain management, environmental testing, assembly processes, and performance validation, ensuring stable supply for the production of ultracentrifuges [5][8] Group 2: Product Features and Applications - The Optima XPN-100 is a flagship ultracentrifuge with a maximum speed of 100,000 rpm and a maximum centrifugal force of 802,000 x g, featuring revolutionary innovations such as intelligent temperature control and dynamic inertia detection, providing efficient and high-purity separation for samples like nucleic acids, proteins, and viral particles [4][11] - This ultracentrifuge plays an irreplaceable role in significant scientific breakthroughs, including the Human Genome Project, mRNA vaccine development, CAR-T cell therapy, and AAV gene vector purification [7] Group 3: Commitment to Local Market - The local production of the Optima XPN-100 is a fulfillment of the company's long-term commitment to Chinese customers, significantly shortening delivery times and enhancing installation, debugging, and after-sales service response speeds [9] - The company plans to produce more models of high-speed centrifuges and cell counters at the Suzhou factory, continuously enhancing local R&D, manufacturing, and service capabilities to support the development of life sciences research in China [9]

7月25日，记者从上海原能细胞生物低温设备有限公司(下称"原能生物")获悉，公司已启动B轮融资。原 能生物总裁庄乾坤告诉记者，目前，原能生物的投前估值大约在18亿元。 同时，庄乾坤透露，原能生物正在筹备科创板独立上市计划。 庄乾坤告诉记者，"目前科创板第五套上市标准恢复。从具体条件来看，我们认为原能生物各方面都符 合该上市标准。这套标准感觉是为我们量身定制的。" 根据上交所科创板股票上市规则，第五套上市标准不对企业营收和净利润规模作出要求，而是以"市值 +研发"为主，即"预计市值不低于人民币40亿元，主要业务或产品需经国家有关部门批准，市场空间 大，目前已取得阶段性成果。医药行业企业需至少有一项核心产品获准开展二期临床试验，其他符合科 创板定位的企业须具备明显的技术优势并满足相应条件。" 此前该套标准一度被实质中断使用。最近一例采用第五套上市标准上市的企业，是2023年6月登陆科创 板的重庆智翔金泰生物制药股份有限公司。直至今年6月，中国证监会主席吴清在2025陆家嘴论坛宣布 重启未盈利企业适用科创板第五套标准上市。 据介绍，原能生物主要从事先进细胞生物自动化低温存储装备的技术研发、产品设计与制造。目前，原 ...